Trial Profile

A Clinical Trial to Evaluate T-VIVA-19 as a Targeted Protein Vaccine Candidate for SARS-CoV-2

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 07 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs T viva 19 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Sorrento Therapeutics

Most Recent Events

07 Jul 2020 New trial record
01 Jul 2020 According to a Sorrento Therapeutics media release, Sorrento plans to take the T-VIVA-19 vaccine candidate through the regulatory steps for clinical trial clearance, while preparing for large scale manufacturing and commercial distribution in parallel.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com